Evonik has sold its TAA derivatives business to Italian chemical company Sabo, which claims to be one of the world's leading manufacturers of light stabilisers. Terms are not being disclosed and the sale is expected to close in early 2023. The sale is part of Evonik’s continuing strategy of focusing its portfolio on speciality chemicals and divesting businesses that no longer fit.
Devi Shah and Fatema Begum of Mayer Brown International look at how companies can deal with insolvency or restructuring issues*
A team led by Mark Walsh and Matthew Kitching from Durham University has published an article in JACS Au, detailing how they found nearly 1,800 conglomerate crystal structures within the Cambridge Structural Database (CSD). These are molecules that are synthesised by racemic methods but which show spontaneously enriched chirality upon crystallisation.
CatSci has made a “significant” investment to support the development of oligonucleotide capability at its site in Cardiff, UK. This follows recent investment in the firm by Keensight Capital to support its strategic growth plans.
David L. Buss, CEO of DB Schenker USA, looks at the key digitisation challenges in distribution
Caldic, the Netherlands-based distributor of life sciences and speciality chemicals, is to merge with Connell of the US, following an agreement by their respective owners, Advent International and Wilbur-Ellis. This should close in Q1 2023, subject to customary conditions and regulatory approvals. Terms were not disclosed and the companies will remain privately owned.
Merck KGaA has revealed at its latest Capital Markets Day that it will continue to focus on its ‘Big Three’ businesses of Process Solutions and Life Science Services, new products in Healthcare and the Semiconductor Solutions arm.
By 2025, these are expected to generate about 80% of targeted sales growth, and more than 50% of total sales. The company remains on track to achieve its mid-term growth target of €25 billion that year and expects to increase sales organically by at least 6%/year on average, about €1 billion/year.
